TCM
EWTX icon

Tang Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Tang Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-431,300
Closed -$7M – 115
2025
Q3 		$7M Hold
431,300
– – 0.27% 80
2025
Q2 		$5.65M Buy
431,300
+131,300
+44% +$1.89M 0.29% 78
2025
Q1 		$6.6M Hold
300,000
– – 0.37% 63
2024
Q4 		$8.01M Buy
+300,000
New +$9.55M 0.53% 51

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Tang Capital Management's EWTX Position: Q4 2025 in Review

Tang Capital Management sold out of Edgewise Therapeutics (EWTX) in Q4 2025, closing a stake of 431,300 shares — an estimated $7M sold.

Tang Capital Management first reported a position in EWTX in Q4 2024 and held it in 4 quarters. The position peaked at $8.01M in Q4 2024. 199 funds tracked by Wall St. Rank hold EWTX as of Q4 2025.

  • Tang Capital Management reported no remaining Edgewise Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Tang Capital Management sold 431,300 Edgewise Therapeutics shares in Q4 2025, an estimated $7M.
  • Tang Capital Management first reported a position in Edgewise Therapeutics in Q4 2024 and held it in 4 quarters.
  • Tang Capital Management's Edgewise Therapeutics position peaked at $8.01M in Q4 2024.
  • 199 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q4 2025.

Based on Tang Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.